Description: Vorolanib (X-82) is an orally active VEGFR/PDGFR dual inhibitor. Target: PDGFR, VEGFR. Smiles: CN(C)C(=O)N1CC[C@@H](C1)NC(=O)c1c(C)[nH]c(\C=C2\C(=O)Nc3ccc(F)cc23)c1C. References: Bendell JC, et al. Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics...

X-82 is a multi-kinase inhibitor. It inhibits VEGFR2, PDGFRbeta, FMS-related tyrosine kinase 3 (FLT3), and c-Kit (IC50s = 1.12, 0.13, 0.63, and 0.14 nM, respectively) and is selective for these kinases over RET and AMP-activated kinase alpha1 (AMPKalpha1, IC50s = 74.1 and 352.2 nM, respectively). X-82 inhibits...